about
HSP27 is a ubiquitin-binding protein involved in I-kappaBalpha proteasomal degradationKRAS Genotype Correlates with Proteasome Inhibitor Ixazomib Activity in Preclinical In Vivo Models of Colon and Non-Small Cell Lung Cancer: Potential Role of Tumor Metabolism.Proteasome inhibitors disrupt the unfolded protein response in myeloma cellsLarge-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progressionA phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapyElevation of proteasomal substrate levels sensitizes cells to apoptosis induced by inhibition of proteasomal deubiquitinases.Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors.Hypoxia-inducible factor α subunit stabilization by NEDD8 conjugation is reactive oxygen species-dependent.Activation of sterile20-like kinase 1 in proteasome inhibitor bortezomib-induced apoptosis in oncogenic K-ras-transformed cells.Proteasome inhibitors-mediated TRAIL resensitization and Bik accumulation.Antitumour effects of antiretroviral therapy.Chemical approaches to controlling intracellular protein degradation.The ubiquitin-proteasome system in HIV replication: potential targets for antiretroviral therapy.Bortezomib induces apoptosis of Epstein-Barr virus (EBV)-transformed B cells and prolongs survival of mice inoculated with EBV-transformed B cellsMolecularly targeted therapies for breast cancer.Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies.Proteasome inhibition and allogeneic hematopoietic stem cell transplantation: a reviewProteasome inhibition as novel treatment strategy in leukaemia.A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors.A Bowman-Birk inhibitor induces apoptosis in human breast adenocarcinoma through mitochondrial impairment and oxidative damage following proteasome 20S inhibitionFollicular thyroid cancer cell growth inhibition by proteosome inhibitor MG132MG-132 inhibits carcinoid growth and alters the neuroendocrine phenotype.Exploiting nature's rich source of proteasome inhibitors as starting points in drug development.ErbB family receptor inhibitors as therapeutic agents in breast cancer: current status and future clinical perspective.Relapsed and refractory pediatric acute myeloid leukemia: current and emerging treatments.Small molecules as pro-apoptotic anticancer agents.Induction of apoptosis by proteasome inhibitors in B-CLL cells is associated with downregulation of CD23 and inactivation of Notch2.Inhibition of heat shock protein response enhances PS-341-mediated glioma cell death.Effect of bortezomib on human neuroblastoma: analysis of molecular mechanisms involved in cytotoxicity.Mutant and misfolded human growth hormone is rapidly degraded through the proteasomal degradation pathway in a cellular model for isolated growth hormone deficiency type II.Maspin augments proteasome inhibitor-induced apoptosis in prostate cancer cells.High-throughput bioluminescence screening of ubiquitin-proteasome pathway inhibitors from chemical and natural sources.Apoptosis induced by proteasome inhibition in cancer cells: predominant role of the p53/PUMA pathway.Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells.Critical role of endogenous Akt/IAPs and MEK1/ERK pathways in counteracting endoplasmic reticulum stress-induced cell death.Proteasome inhibitor PS-341 down-regulates prostate-specific antigen (PSA) and induces growth arrest and apoptosis of androgen-dependent human prostate cancer LNCaP cells.Proteasome inhibitor PS-341 induces growth arrest and apoptosis of non-small cell lung cancer cells via the JNK/c-Jun/AP-1 signaling.Combination of proteasomal inhibitors lactacystin and MG132 induced synergistic apoptosis in prostate cancer cells.The final cut: how ERAP1 trims MHC ligands to size.Evidence for the Critical Roles of NF-κB p65 and Specificity Proteins in the Apoptosis-Inducing Activity of Proteasome Inhibitors in Leukemia Cells.
P2860
Q24679412-5A5C3017-F69D-431F-95AE-815912A864E1Q27853300-4967C90E-928B-40B1-BA7F-2BFABC9AA225Q28155919-EDC30859-DC1C-44CC-81C5-5687ECBD4D64Q29615223-8A16BCF3-1C0B-4CC4-BD98-53B60BF73AA7Q33380300-B3B00157-783B-4384-827F-DB75710496E4Q34294233-5C5C5E39-28E7-4395-930F-5CDDEE915B28Q34313195-296E51DE-F06D-497B-AEE5-1684984ADB81Q34606086-CD84097E-F099-4BE0-BCB8-EEF1721475CEQ34696370-1C18CDE2-A54B-438A-B953-14F5234A0A31Q35070129-B2FD0B68-24C6-4097-ACAA-E4890B7AC222Q35934144-F11EFA06-A53C-4985-8151-8A78E4152226Q35942581-77E6C32A-C536-4F86-8814-C029EFA3AC76Q36066214-985B4E47-5B39-4A11-B7F9-3DFDA9BE7503Q36098835-9E7E2EEC-D783-4C6A-8877-B1E630C18DB8Q36108605-B474C5FF-05CE-4980-BD9E-1CA6C0E2D020Q36238764-E4184851-0B60-46FC-A5A6-3E556B0871B3Q36408216-54AFD722-1953-4B72-A502-B13A73E4D64DQ36513273-428F3288-874A-4339-AB02-EDADF33E61F4Q36520182-3655B320-DA38-41FE-8165-8B894B7E1231Q37164347-971A9C80-E437-4C92-A46E-AC3EBBD29877Q37314468-23D9A4D6-C766-4A33-9348-5C7330D86733Q37480580-19D70830-CC7D-49FC-9868-B2E84B7BF41BQ37951013-D80EBAB5-76FA-4AF6-A853-C4482F009B00Q37970020-78CEC8E2-FCEA-4883-BB1D-450CFDF1AFDFQ38155455-40104913-825F-4E71-A1B9-9181DBE5074EQ38162939-DE294F7B-3050-4B39-B449-5CC53E6D9F94Q38333825-CC093224-0D36-4CFD-9D69-A1A5E7FDA748Q39512205-EE4E4EF1-831D-42B5-A188-DA6B39AB0B57Q39655015-5B72D626-DA55-4777-B895-E228C818A2E8Q40069859-1027692F-4BAC-47C8-BB3A-B4D5324CDC6EQ40141260-8ED7027C-5C67-4A70-B9BF-270E155FA3F3Q40194092-745E99AD-8F7A-4B9B-B4A2-08D6085EAD2EQ40230307-C4E3EA05-82CF-48B7-8C34-BC2C241CB16DQ40310345-6F7999C7-E997-478C-AE68-F415F372DEE8Q40520566-8269CB08-6915-4694-BC8B-E7E9E18C0274Q40579506-AE242CDE-6954-4975-AF7D-9AAF46DCEA8FQ40589715-2C1DF11D-1065-423A-8D38-27FB927BD084Q41472341-9D804016-C718-4B30-A34A-304D6EE0CF6DQ44226360-6CFFB2F1-A223-46D1-B4C4-1D8EEE11F528Q45784186-F8FDEA50-5294-4DEB-A395-AB923EDC0828
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Proteasome inhibitors as new anticancer drugs.
@ast
Proteasome inhibitors as new anticancer drugs.
@en
Proteasome inhibitors as new anticancer drugs.
@nl
type
label
Proteasome inhibitors as new anticancer drugs.
@ast
Proteasome inhibitors as new anticancer drugs.
@en
Proteasome inhibitors as new anticancer drugs.
@nl
prefLabel
Proteasome inhibitors as new anticancer drugs.
@ast
Proteasome inhibitors as new anticancer drugs.
@en
Proteasome inhibitors as new anticancer drugs.
@nl
P1476
Proteasome inhibitors as new anticancer drugs.
@en
P2093
Julian Adams
P304
P356
10.1097/00001622-200211000-00007
P577
2002-11-01T00:00:00Z